Current PSA level-Between 1 to 4 Posts on Medivizor
Navigation Menu

Current PSA level-Between 1 to 4 Posts on Medivizor

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Posted by on May 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...

Read More

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of phosphodiesterase-5 (PDE5) inhibitor tadalafil (Cialis) for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) after low-dose-rate (LDR) brachytherapy (BT) in patients with localized prostate cancer. The data showed that tadalafil improved the LUTS and ED outcomes...

Read More

Evaluating the long-term outcomes of regional (hockey-stick) prostate cryoablation in men with low- or intermediate-risk prostate cancer

Evaluating the long-term outcomes of regional (hockey-stick) prostate cryoablation in men with low- or intermediate-risk prostate cancer

Posted by on Feb 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and quality of life outcomes after prostate cryoablation (a process that uses extreme cold to destroy prostate tumor) treatment for patients with low and intermediate-risk prostate cancer (PCa). The data showed that the treatment had good outcomes with minimal impact on urinary and sexual...

Read More

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Do statins help the treatment of patients with prostate cancer using androgen-deprivation therapy?

Posted by on Jan 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study explored the outcomes of statin (cholesterol-lowering drugs) treatment in patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT). The authors found that the combination of statins and ADT improved the outcomes of these patients and intermittent ADT (IADT) increased the time...

Read More

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Posted by on Dec 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...

Read More

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Posted by on Nov 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...

Read More

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

Posted by on Jul 19, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...

Read More

The use of relugolix in addition to radiotherapy in patients with prostate cancer

Posted by on May 2, 2020 in Prostate cancer | 0 comments

In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...

Read More

Searching for patients with prostate cancer to test low-dose or high-dose brachytherapy

Posted by on May 28, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...

Read More

Looking for men with high-risk prostate cancer features after prostate surgery to trial a type of radiation therapy

Posted by on Apr 17, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of radiation therapy, in treating patients with high-risk prostate cancer features after radical prostatectomy (surgery to remove the prostate gland). The main outcome to be measured will be freedom from failure. Failure is evidence that the cancer has returned. Patients will be followed up for 5...

Read More